Pro Plex 450
Hauptinformation
- Handelsname:
- Pro Plex 450
- Wirkstoff:
- Prochloraz
- Verfügbar ab:
- Agriplex
- INN (Internationale Bezeichnung):
- Prochloraz
- Darreichungsform:
- EC Emulsionskonzentrat
- Verwenden für:
- Pflanzen
- Art der Medizin:
- Agrochemisch
Dokumenten
- für die Allgemeinheit:
- Packungsbeilage
-
- Information für medizinisches Fachpersonal:
- Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.
Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.
Lokalisierung
- Erhältlich in:
-
Schweiz
- Sprache:
- Deutsch
Therapeutische Informationen
- Therapiegruppe:
- Fungizid
Weitere Informationen
Status
- Quelle:
- UFAG - Ufficio federale dell'agricoltura. OFAG - Office fédéral de l'agriculture. BLW - Bundesamt für Landwirtschaft.
- Zulassungsnummer:
- F-2421
- Letzte Änderung:
- 15-11-2018
Packungsbeilage: zusammensetzung, kinische angaben, nebenwirkungen, wechselwirkungen, dosierung, schwangerschaft, stillzeit
Handelsbezeichnung: Pro Plex 450
(Parallelimport)
Pflanzenschutzmittelverzeichnis (Stand: 06.11.2018)
Bewilligung beendet: Ausverkaufsfrist: 31.05.2018, Aufbrauchsfrist: 31.05.2019
Produktkategorie:
Ausl. Bewilligungsinhaber:
Eidg. Zulassungsnummer:
Fungizid
Agriplex
F-2421
Stoff(e):
Gehalt:
Formulierungscode:
Wirkstoff: Prochloraz 41.5 % 450 g/l
EC Emulsionskonzentrat
Anwendungen
A Kultur
Schaderreger/Wirkung
Dosierungshinweise
Auflagen
F Gerste
Netzfleckenkrankheit der Gerste
Rhynchosporium-Blattfleckenkrankheit
Aufwandmenge: 1 l/ha
Anwendung: Stadium 31-51 (BBCH).
F Weizen Halmbruchkrankheit des Getreides
Aufwandmenge: 1 l/ha
Anwendung: Stadium 30-32 (BBCH).
Auflagen und Bemerkungen:
Maximal 1 Behandlung pro Kultur.
Gefahrenkennzeichnungen:
Es gilt die Einstufung und Kennzeichnung der ausländischen Originaletikette..
Zusätzliche Schweizerische Gefahrenkennzeichnungen:
SP 1 Mittel und/oder dessen Behälter nicht in Gewässer gelangen lassen.
Im Zweifelsfall gelten einzig die Originaldokumente der Zulassung. Die Erwähnung eines Produktes,
Wirkstoffes oder einer Firma stellt keine Empfehlung dar und bedeutet nicht, dass sich das Produkt im
Verkauf befindet.
- Der Zugriff auf dieses Dokument steht nur registrierten Benutzern zur Verfügung.
Registrieren Sie sich jetzt für den Vollzugriff
18-2-2019

Medline Canada, Corp. recalls certain lots of Remedy Phytoplex Nourishing Skin Cream
The affected products are being recalled due to the presence of certain species of mould, Penicillium chrysogenum and Penicillium flavigenum. The affected products are not likely to cause an adverse health consequence in healthy individuals, however, may pose a risk to people with weakened immune systems.
Health Canada
30-1-2019

Statement from FDA Commissioner Scott Gottlieb, M.D., on 2019 efforts to advance the development of complex generics to improve patient access to medicines
FDA Commissioner on 2019 efforts to advance the development of complex generics to improve patient access to medicines
FDA - U.S. Food and Drug Administration
26-1-2019

Literature review in support of adjuvanticity/immunogenicity assessment of proteins
Published on: Fri, 25 Jan 2019 Based on the risk assessment of genetically modified plants, according to Implementing Regulation (EU) No 503/201321 “In cases when known functional aspects of the newly expressed protein or structural similarity to known strong adjuvants may indicate possible adjuvant activity, the applicant shall assess the possible role of these proteins as adjuvants”. To further investigate the topic, an EFSA procurement was launched requesting a comprehensive literature review and cri...
Europe - EFSA - European Food Safety Authority EFSA Journal
16-1-2019

FDA approves first generic version of Sabril to help treat seizures in adults and pediatric patients with epilepsy
FDA approved the first generic version of Sabril for treating complex partial seizures, as an adjunctive therapy in certain patients.
FDA - U.S. Food and Drug Administration
18-12-2018

eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course (Amsterdam), BCN Amsterdam Arena, Atlas Arena Complex Amsterdam, The Netherlands, from 14/02/2019 to 15/02/2019
eXtended EudraVigilance Medicinal Product Dictionary face-to-face training course (Amsterdam), BCN Amsterdam Arena, Atlas Arena Complex Amsterdam, The Netherlands, from 14/02/2019 to 15/02/2019
Europe - EMA - European Medicines Agency
17-12-2018

December 13, 2018: Floridian Pleads Guilty in Complex Fraud Scheme Related to the Processing of Credit Card Payments
December 13, 2018: Floridian Pleads Guilty in Complex Fraud Scheme Related to the Processing of Credit Card Payments
FDA - U.S. Food and Drug Administration
5-12-2018

Public health risks associated with food‐borne parasites
Published on: Tue, 04 Dec 2018 Parasites are important food‐borne pathogens. Their complex lifecycles, varied transmission routes, and prolonged periods between infection and symptoms mean that the public health burden and relative importance of different transmission routes are often difficult to assess. Furthermore, there are challenges in detection and diagnostics, and variations in reporting. A Europe‐focused ranking exercise, using multicriteria decision analysis, identified potentially food‐borne ...
Europe - EFSA - European Food Safety Authority Publications
9-11-2018

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials
Published on: Wed, 07 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of the additive Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials. It is a family of mixtures combining the four lanthanides lanthanum (La), europium (Eu), gadolinium (Gd) and/or terbium (Tb) in different proportions as their 1,4‐benzene dicarboxylate complexes, used as a taggant in plastics for authentication and ...
Europe - EFSA - European Food Safety Authority Publications
17-10-2018

Applicability of in silico tools for the prediction of dermal absorption for pesticides
Published on: Tue, 16 Oct 2018 00:00:00 +0200 Based on the “Human in vitro dermal absorption datasets” published as supporting information to the revised EFSA Guidance on Dermal Absorption, in silico models for prediction of absorption across the skin have been evaluated. For this evaluation, a systematic literature search and review was performed, identifying 288 publications describing mathematical models for prediction of dermal absorption. Eleven models potentially relevant to the regulatory assessm...
Europe - EFSA - European Food Safety Authority Publications
10-10-2018

Credelio 450 mg ad us. vet., Kautabletten fuer Hunde
● Die Neuzulassung erfolgte am 10.10.2018.
Institut für Veterinärpharmakologie und toxikologie
9-10-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines
FDA issued a new series of guidance documents that will advance the development of generic transdermal and topical delivery systems
FDA - U.S. Food and Drug Administration
9-10-2018

Notice of call for expressions of interest - Multiplex serologie
France - Agence Nationale du Médicament Vétérinaire
11-9-2018

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies
Published on: Mon, 27 Aug 2018 00:00:00 +0200 Antimicrobial resistance (AMR) represents a major challenge for Public Health and the scientific community, and requires immediate and drastic solutions. Acquired resistance to certain antimicrobials is already widespread to such an extent that their efficacy in the treatment of certain life‐threatening infections is already compromised. To date, the emergence and spread of AMR has been attributed to the use, misuse or indiscriminate use of antibiotics as th...
Europe - EFSA - European Food Safety Authority Publications
29-8-2018

Review of the existing maximum residue levels for prochloraz according to Article 12 of Regulation (EC) No 396/2005
Published on: Mon, 27 Aug 2018 00:00:00 +0200 According to Article 12 of Regulation (EC) No 396/2005, EFSA has reviewed the maximum residue levels (MRLs) currently established at European level for the pesticide active substance prochloraz. To assess the occurrence of prochloraz residues in plants, processed commodities, rotational crops and livestock, EFSA considered the conclusions derived in the framework of Directive 91/414/EEC, the MRLs established by the Codex Alimentarius Commission as well as th...
Europe - EFSA - European Food Safety Authority Publications
21-8-2018

Orphan designation: Codon-optimised human ornithine transcarbamylase mRNA complexed with lipid-based nanoparticles, for the: Treatment of ornithine transcarbamylase deficiency
Europe - EMA - European Medicines Agency
26-7-2018

Opinion/decision on a Paediatric investigation plan (PIP): Xeomin, Bocouture, Clostridium botulinum neurotoxin type A (150 kD), free from complexing proteins, Therapeutic area: Neurology/Ophthalmology
Europe - EFSA - European Food Safety Authority EFSA Journal
25-7-2018
![Opinion/decision on a Paediatric investigation plan (PIP): -, Calcium, N,N'-1,2-ethanediylbis[N-[[3-(hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycine] manganese complexes, Therapeutic area: Other/Oncology](/web/assets/global/img/flags/eu.png)
Opinion/decision on a Paediatric investigation plan (PIP): -, Calcium, N,N'-1,2-ethanediylbis[N-[[3-(hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycine] manganese complexes, Therapeutic area: Other/Oncology
Europe - EFSA - European Food Safety Authority EFSA Journal
3-7-2018

DKMA Update June 2018
In this issue of DKMA Update you can read about new rules on private individuals' import of medicines, Danish Medicines Agency being key driver in European solution for complex clinical trials and much more.
Danish Medicines Agency
6-6-2018

January 10, 2018: Six Charged in Complex Fraud Involving Fraudulent Processing of Credit Card Payments
January 10, 2018: Six Charged in Complex Fraud Involving Fraudulent Processing of Credit Card Payments
FDA - U.S. Food and Drug Administration
6-6-2018

June 5, 2018: Floridian Charged in Complex Fraud Scheme Related to the Processing of Credit Card Payments
June 5, 2018: Floridian Charged in Complex Fraud Scheme Related to the Processing of Credit Card Payments
FDA - U.S. Food and Drug Administration
29-5-2018

Arzneimittelstudien für neue, gezielte Therapieansätze: 300 Experten beraten in Bonn Chancen und Herausforderungen komplexer klinischer Studien.
Pressemitteilung Nr. 13/17
Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte
18-5-2018

7K and Poseidon 4500 by Shoreside Enterprises: Voluntary Recall - Due to Presence of Undeclared Sildenafil and/or Tadalafil
Use of products with the undeclared active ingredients, sildenafil and tadalafil, may pose a threat to consumers because the active ingredient may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may cause a significant drop in blood pressure that may be life threatening. Among the adult male population who are most likely to use these products, adult males who use nitrates for cardiac conditions are the most at risk from these products. These products are considered ta...
FDA - U.S. Food and Drug Administration
17-5-2018

Shoreside Enterprises Issues Voluntary Nationwide Recall of 7K and Poseidon 4500 (Extreme 1000 Mg) Due to Presence of Undeclared Sildenafil and Tadalafil
Shoreside Enterprises, Inc. is voluntarily recalling 7K (Lot specific: Lot #RO) and Poseidon 4500 (Extreme 1000 mg) (Lot specific: Lot #20117BL) to the consumer level. FDA analysis found the samples of these products to contain undeclared Sildenafil and/or Tadalafil. Sildenafil and Tadalafil are active ingredients in two FDA-approved prescription drugs used for the treatment of erectile dysfunction (ED).
FDA - U.S. Food and Drug Administration
17-5-2018

Orphan designation: genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII, for the: Treatment of epidermolysis bullosa
Europe - EMA - European Medicines Agency
10-5-2018

Medline Remedy Essentials No-Rinse Cleansing Foam: Avoid Using - Multistate Outbreak of Burkholderia Cepacia Complex
CDC reports that there are 10 confirmed cases of infection caused by bacteria within the Burkholderia cepacia complex, also commonly called B. cepacia, in three states: California (2), Pennsylvania (7), and New Jersey (1). These patients were already hospitalized for acute conditions and acquired the infections while hospitalized. The infections have been linked to the Medline product, Remedy Essentials No-Rinse Cleansing Foam.
FDA - U.S. Food and Drug Administration
9-5-2018

FDA Investigates Multistate Outbreak of B. cepacia Complex Linked to Medline Remedy Essentials No-Rinse Cleansing Foam (FDA Announcement)
FDA Investigates Multistate Outbreak of B. cepacia Complex Linked to Medline Remedy Essentials No-Rinse Cleansing Foam (FDA Announcement)
FDA - U.S. Food and Drug Administration
20-2-2019

Opinion/decision on a Paediatric investigation plan (PIP): Complex of povidone and iodine,dexamethasone (SHP640), decision type: , therapeutic area: , PIP number: P/0369/2018
Opinion/decision on a Paediatric investigation plan (PIP): Complex of povidone and iodine,dexamethasone (SHP640), decision type: , therapeutic area: , PIP number: P/0369/2018
Europe - EMA - European Medicines Agency
14-2-2019

EU/3/18/2012 (IDEA Innovative Drug European Associates (Ireland) Limited)
EU/3/18/2012 (Active substance: Genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII) - Transfer of orphan designation - Commission Decision (2019)1356 of Thu, 14 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003115
Europe -DG Health and Food Safety
17-1-2019

Holoclar (Chiesi Farmaceutici S.p.A.)
Holoclar (Active substance: Ex vivo expanded autologous human corneal epithelial cells containing stem cells) - Centralised - Annual renewal - Commission Decision (2019)272 of Thu, 17 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2450/R/21
Europe -DG Health and Food Safety
11-1-2019

Opinion/decision on a Paediatric investigation plan (PIP): Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins, decision type: , therapeutic area: , PIP number: P/0338/2018
Opinion/decision on a Paediatric investigation plan (PIP): Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins, decision type: , therapeutic area: , PIP number: P/0338/2018
Europe - EMA - European Medicines Agency
19-12-2018

EU/3/13/1169 (Richardson Associates Regulatory Affairs Ltd)
EU/3/13/1169 (Active substance: Lipid-complexed cisplatin) - Transfer of orphan designation - Commission Decision (2018)9013 of Wed, 19 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002651
Europe -DG Health and Food Safety
26-11-2018

As device technology evolves and becomes increasingly complex, #FDA needs to keep pace. Our proposed changes to the 510(k) clearance pathway will allow FDA to retire outdated predicates and use new technologies to promote innovation and improved safety.
As device technology evolves and becomes increasingly complex, #FDA needs to keep pace. Our proposed changes to the 510(k) clearance pathway will allow FDA to retire outdated predicates and use new technologies to promote innovation and improved safety. https://go.usa.gov/xPHdE
FDA - U.S. Food and Drug Administration
30-7-2018

Zalmoxis (MolMed S.p.A.)
Zalmoxis (Active substance: Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (?LNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)) - Centralised - Renewal - Commission Decision (2018)5118 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2801/R/10
Europe -DG Health and Food Safety
29-6-2018

EU/3/18/2033 (Real Regulatory Limited)
EU/3/18/2033 (Active substance: Codon-optimised human ornithine transcarbamylase mRNA complexed with lipid-based nanoparticles) - Orphan designation - Commission Decision (2018)4178 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/022/18
Europe -DG Health and Food Safety
28-6-2018
Ovaleap 300 I.E./0,5 ml / -450 I.E./0,75 ml / -900 I.E./1,5 ml Injektionslösung
Rote - Liste
30-5-2018

Hepsera (Gilead Sciences Ireland UC)
Hepsera (Active substance: adefovir dipivoxil) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3450 of Wed, 30 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/485/T/78
Europe -DG Health and Food Safety
18-4-2018

EU/3/18/2012 (IDEA Innovative Drug European Associates Limited)
EU/3/18/2012 (Active substance: Genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII) - Orphan designation - Commission Decision (2018)2408 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/244/17
Europe -DG Health and Food Safety